前立腺がん

プレスリリース

エンザルタミド、ホルモン感受性転移性前立腺がんのrPFSを有意に延長;第Ⅲ相ARCHES

2019-02-18
米・Pfizer

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer